Daily Cardiology Research Analysis
Three impactful cardiology studies stood out today: a translational study reveals HDAC3-driven epigenetic dysregulation in aortic valve disease and suggests metformin as a potential therapy; a meta-analysis shows that left atrial appendage patency on cardiac CT after occlusion is linked to higher thromboembolic risk; and a very large real-world analysis clarifies that testosterone therapy increases atrial fibrillation and venous thromboembolism in cis men but not in trans men.
Summary
Three impactful cardiology studies stood out today: a translational study reveals HDAC3-driven epigenetic dysregulation in aortic valve disease and suggests metformin as a potential therapy; a meta-analysis shows that left atrial appendage patency on cardiac CT after occlusion is linked to higher thromboembolic risk; and a very large real-world analysis clarifies that testosterone therapy increases atrial fibrillation and venous thromboembolism in cis men but not in trans men.
Research Themes
- Epigenetic-metabolic regulation in valvular heart disease and therapeutic repurposing
- Imaging-detected residual leaks after LAA occlusion and thromboembolic risk
- Cardiovascular safety profile of testosterone therapy across cis and trans men
Selected Articles
1. Epigenetic dysregulation of energy homeostasis drives aortic valve stenosis that is treatable with metformin.
Using human valves, conditional mouse models, and transcriptomics, the authors show that loss of HDAC3 increases H3K27ac and activates mitochondrial programs, driving noncalcific aortic valve stenosis with fibrosis and failure. Metformin restored redox balance and collagen organization and improved valve function in Hdac3-deficient mice, and retrospective clinical data associated metformin with lower prevalence and slower progression of stenosis.
Impact: Reveals an epigenetic-metabolic mechanism of aortic valve disease and identifies metformin as a plausible, already-available therapy, addressing a major unmet need.
Clinical Implications: Supports mechanistic rationale to test metformin in prospective trials for noncalcific aortic valve disease; suggests HDAC3 and mitochondrial pathways as therapeutic targets.
Key Findings
- HDAC3 activity is reduced in diseased human valve regions with increased H3K27ac.
- Valve-specific HDAC3 deletion in mice causes fibrosis, disorganized collagen, increased oxidative phosphorylation, and early mortality.
- Metformin treatment restores redox balance, preserves collagen structure, and improves valve function in Hdac3-deficient mice.
- Retrospective clinical analysis associates metformin therapy with lower prevalence and slower progression of aortic valve stenosis.
Methodological Strengths
- Integrative translational design combining human tissue profiling, conditional mouse genetics, and mechanistic analyses
- Therapeutic validation with a clinically available drug and supportive retrospective human data
Limitations
- Clinical component is retrospective and may be confounded
- Noncalcific model may not capture all phenotypes of calcific aortic valve disease
Future Directions: Prospective randomized trials of metformin in early aortic valve disease; exploration of HDAC3-modulating strategies and mitochondrial targets in human valve fibroblasts.
Aortic valve stenosis is a progressive and increasingly prevalent disease in older adults, with no approved pharmacologic therapies to prevent or slow its progression. Although genetic risk factors have been identified, the contribution of epigenetic regulation remains poorly understood. Here, we demonstrated that histone deacetylase 3 (HDAC3) maintains aortic valve structure by suppressing mitochondrial biogenesis and preserving extracellular matrix integrity in valvular interstitial fibroblasts. Human stenoti
2. Outcomes of Left Atrial Appendage Patency After Device Closure Detected by Cardiac CT: A Meta-Analysis.
Across 17 studies with 2,036 patients, any LAA patency on cardiac CT after occlusion was associated with nearly doubled thromboembolism risk (pooled OR 1.87), translating to 28 additional events per 1,000. Peridevice leak showed a similar but non-significant trend. Bayesian analyses corroborated increased risk probabilities.
Impact: Provides quantitative, imaging-based risk stratification after LAA occlusion and challenges the assumption that small residual leaks are benign.
Clinical Implications: Consider routine CT-based assessment of LAA patency, and individualized decisions on anticoagulation continuation or leak closure in patients with residual patency.
Key Findings
- Any LAA patency by CT nearly doubled thromboembolism risk (pooled OR 1.87; absolute risk difference ~2.8%).
- Peridevice leak showed a non-significant trend toward increased risk (pooled OR 1.50).
- Bayesian analysis supported a high posterior probability that LAA patency increases thromboembolism risk (≈98.5% for ARD > 0).
Methodological Strengths
- Use of both traditional and Bayesian meta-analytic frameworks
- CT-based standardized detection across multiple studies
Limitations
- Heterogeneity in leak definitions and imaging protocols
- Predominantly observational data limiting causal inference
Future Directions: Prospective studies to define management thresholds for CT-detected patency and to test anticoagulation or leak-closure strategies informed by CT.
BACKGROUND: Residual leaks are common after left atrial appendage occlusion (LAAO). OBJECTIVES: The authors aimed to systematically evaluate the prognostic implications of residual left atrial appendage (LAA) patency and peridevice leaks (PDLs) detected by cardiac computed tomography (CT) following LAAO. METHODS: The authors used traditional meta-analytical methods and a Bayesian framework to assess the probability of increased risks associated with these residual leaks. RESULTS: Seventeen studies encompassi
3. Testosterone therapy and the risk of atrial fibrillation, venous thromboembolism and cardiovascular events in cis men with hypogonadism and trans men.
In 5-year propensity-matched analyses, cis men on testosterone had lower myocardial infarction risk (HR 0.94) but higher risks of atrial fibrillation (HR 1.27) and acute PE/DVT (HR 1.26). Among trans men, testosterone therapy was not associated with increased cardiovascular events compared with untreated trans or cis men, and suicide attempts were lower versus untreated trans men (HR 0.52).
Impact: Large, contemporary real-world analysis clarifies differential cardiovascular safety signals of testosterone therapy in cis versus trans men and quantifies arrhythmic and thromboembolic risks.
Clinical Implications: For cis men, shared decision-making should weigh potential MI risk reduction against increased AF and VTE; consider rhythm surveillance and VTE risk mitigation. Data support cardiovascular safety in trans men within 5 years, while emphasizing mental health benefits.
Key Findings
- Cis men on testosterone: lower MI risk (HR 0.94, 95% CI 0.89-0.99) with higher AF (HR 1.27) and PE/DVT (HR 1.26) risks over 5 years.
- Trans men on testosterone: no increase in cardiovascular outcomes versus untreated trans or untreated cis men.
- Lower suicide attempt rate in trans men receiving testosterone versus untreated trans men (HR 0.52).
Methodological Strengths
- Very large propensity score–matched cohorts across multiple comparisons
- Five-year follow-up with hard outcomes stratified by gender identity
Limitations
- Observational design with potential residual confounding and misclassification
- Lack of dose/duration granularity and adjudicated event validation in claims data
Future Directions: Prospective studies to define mechanisms of AF/VTE risk under testosterone and to optimize monitoring and thromboprophylaxis strategies; longer-term outcomes in trans men.
OBJECTIVE: While the cardiovascular safety of testosterone therapy in men remains controversial, limited data exist for trans men treated with testosterone. We assessed cardiovascular events, mortality, and suicide attempts under testosterone therapy in both cis men with hypogonadism and trans men. METHODS: Participants were recruited from the TriNetX Research network. We compared 117 908 cis men with hypogonadism treated with testosterone with 1:1 propensity score matched cis men not treated. We compar